Cs-137 Irradiator for new Fitzsimons Campus

描述(申请人提供)：现代辐照仪是生物学和医学的重要研究工具。该提案确定了12个主要用户，要求使用具有Cs-137源的高活度辐照器。该仪器由JL牧羊人公司制造，型号为JL81型，申请中包括州和联邦监管法律要求的配件。科罗拉多大学丹佛分校和健康科学中心(UCDHSC)的研究人员目前使用的是9号和科罗拉多大道已经到位的Co-60源。该校自1978年以来一直在丹佛，并因该校更换了放射源。超过90%的使用放射源的调查人员已经搬到了我们位于奥罗拉的菲茨西蒙斯新园区。剩下的教职员工在第九大道。校园将在2007年前搬到Fitzsimons，届时Co-60源将被淘汰，因为新的源和搬迁的成本比购买新的辐照器更昂贵。为了继续NIH资助的这些研究人员的研究，Fitzsimons现场的一个新的辐照器将是必不可少的。该机构已经在菲茨西蒙斯遗址的研究综合体I确定了这样一个仪器的空间。选择具有Cs-137源的JL81辐照器是因为它具有广泛的体外和体内应用的灵活性，从培养细胞的照射到动物的照射，从小鼠到绵羊的照射，以及深剂量或浅剂量照射的衰减。该放射设施将作为科罗拉多大学癌症中心(UCCC)的一个新的核心设施进行管理。UCCC作为基质癌症中心有17年的经验，拥有成熟和功能强大的结构，鼓励生产力，促进互动和合作，并将UCCC定位为最大限度地利用UCDHSC、其附属机构和社区的资源。15个主要用户将提出他们NIH资助的研究中不可或缺的问题，这种仪器的可用性将显著增强，而且在许多情况下对他们的NIH资助的研究至关重要。此外，预计获得JL81辐照器并将其安置在菲茨西蒙斯新园区将促进癌症中心成员之间新合作的发展，这将导致更多的用户获得NIH级别的资金。相关性：获得资金为UCDHSC Fitzsimons校区购买新的JL 81辐照器将为建立与癌症诊断和治疗相关的研究基础提供重要渠道。许多拥有NIH资助的癌症中心成员致力于根除癌症，并意识到临床前研究对于将研究结果转化为人类临床试验至关重要。JL 81辐照仪是这一癌症研究基础的重要组成部分，将促进UCDHSC Fitzsimons新校区进行必要的临床前实验。

DESCRIPTION (provided by applicant): A modern irradiator is an essential research tool for biology and medicine. Twelve major users are identified in this proposal that is requesting a high activity irradiator with a Cs-137 source. The instrument is made by the JL Shepherd Company, Model JL81, and included in the request are accessories required by state and federal regulatory laws. Investigators at the University of Colorado at Denver and Health Sciences Center (UCDHSC) currently use a Co-60 source that has been in place at the 9th and Colorado Blvd. campus in Denver since 1978 and is due for replacement of the radioactive source. Over 90% of the investigators that use the radiation source have moved to our new Fitzsimons campus in Aurora. The remaining faculty at the 9th Ave. campus will move to Fitzsimons by 2007, at which time the Co-60 source will be decommissioned because the cost of a new source and moving is more expensive that buying a new irradiator. A new irradiator at the Fitzsimons site will be essential for continuing the NIH-funded research of these investigators. The institution has identified space for such an instrument in Research Complex I at the Fitzsimons site. The JL81 irradiator with a Cs-137 source was selected because it has the flexibility of a wide range of in vitro and in vivo applications ranging from the irradiation of cells in culture to that of animals, from mice to sheep, and attenuation for deep dose or superficial irradiation applications. The irradiation facility will be managed as a new core facility in the University of Colorado Cancer Center (UCCC). The UCCC has 17 years of experience as a matrix cancer center and has a mature and functional structure that encourages productivity, promotes interactions and collaboration, and positions the UCCC to maximize the resources at the UCDHSC, its affiliates, and the community. The 15 major users will pursue questions integral to their NIH-funded research and the availability of this instrumentation will significantly enhance, and in many cases is crucial for, their NIH-funded research. In addition, it is expected that obtaining the JL81 irradiator and housing it at the new Fitzsimmons campus will facilitate development of new collaborations among cancer center members that will result in additional users with NIH level funding. Relevance: Obtaining funds to purchase a new JL 81 irradiator for the UCDHSC Fitzsimons campus will provide an important conduit for building upon a foundation of research related to cancer diagnosis and therapy. Many Cancer Center members with NIH funding are committed to the eradication of cancer and realize that preclinical investigations are crucial for translating findings into human clinical trials. The JL 81 irradiator is an important component of this foundation of cancer research and will facilitate the preclinical experiments necessary for translation at the new UCDHSC Fitzsimons campus.